| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 2, 2020CoSara tests for tuberculosis, malaria, hepatitis B, hepatitis C, and human papillomavirus recently granted regulatory approval by CDSCO to formally launch at India Diagnostic Expo
Salt Lake City, Utah – January 2, 2020 – Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of...
-
Dec 11, 2019
Salt Lake City, Utah – December 11, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), was recently featured in an article on genomeweb.com titled “Co-Diagnostics Continues Global Expansion With...
-
Dec 10, 2019Vector Smart™ NAM-e multiplex PCR test to provide proactive defense against mosquito populations carrying the deadly eastern equine encephalitis virus
Salt Lake City, Utah – December 10, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,...
-
Dec 3, 2019CoSara Saragene™ tests for tuberculosis, malaria, hepatitis B, hepatitis C, and human papillomavirus now available for sale and distribution as in vitro diagnostics
Salt Lake City, Utah – December 3, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,...
-
Nov 13, 2019Revenue includes sales of infectious disease, mosquito abatement products and AgBio primer design services
Salt Lake City, Utah – November 13, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,...